Ascendis Pharma A/S

NASDAQ:ASNDUnited States

Yesterday

Show headlines and story abstract

• Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH, from 9:29AM ET on Monday May 13, 2024 by MT Newswires

  9:29AM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: ASND
  09:29 AM EDT, 05/13/2024 (MT Newswires) -- Ascendis Pharma (ASND) said Monday that two-year data from an analysis of a late-stage trial showed "significant and sustained improvements in renal function" in people with chronic hypoparathyroidism treat...

• Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon(TM) PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial, from 8:30AM ET on Monday May 13, 2024 by GlobeNewswire

  8:30AM ET on Monday May 13, 2024 by GlobeNewswire
  Companies Mentioned: ASND

• Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon(TM) PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial, from 8:30AM ET on Monday May 13, 2024 by Dow Jones

  8:30AM ET on Monday May 13, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the potential for TransCon PTH to address concerns about soft-tissue calcifications and decreased kidney function associated with conventional therapy, (ii) TransCon PTH's PDUFA date of May 14, 2024, (iii) Ascendis' ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company and (iv) Ascendis' use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024 and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.